TY - JOUR AU - Kiss, Szabolcs AU - Pintér, József AU - Molontay, Roland AU - Nagy, Marcell AU - Borbásné Farkas, Kornélia AU - Sipos, Zoltán AU - Fehérvári, Péter AU - Pecze, László AU - Földi, Mária AU - Vincze, Áron AU - Takács, Tamás AU - Czakó, László AU - Szabó-Halász, Adrienn AU - Boros, Eszter AU - Hamvas, József AU - Varga, Márta AU - Mickevicius, Artautas AU - Faluhelyi, Nándor AU - Farkas, Orsolya AU - Váncsa, Szilárd AU - Nagy, Rita AU - Bunduc, Stefania AU - Hegyi, Péter Jenő AU - Márta, Katalin AU - Borka, Katalin AU - Doros, Attila AU - Hosszúfalusi, Nóra AU - Zubek, László AU - Erőss, Bálint Mihály AU - Molnár, Zsolt AU - Párniczky, Andrea AU - Hegyi, Péter AU - Szentesi, Andrea Ildikó ED - Kiss, Szabolcs / Collaborator ED - Farkas, Nelli / Collaborator ED - Sipos, Zoltán / Collaborator ED - Fehérvári, Péter / Collaborator ED - Pecze, László / Collaborator ED - Földi, Mária / Collaborator ED - Vincze, Áron / Collaborator ED - Takács, Tamás / Collaborator ED - Czakó, László / Collaborator ED - Halász, Adrienn / Collaborator ED - Boros, Eszter / Collaborator ED - Hamvas, József / Collaborator ED - Varga, Márta / Collaborator ED - Mickevicius, Artautas / Collaborator ED - Faluhelyi, Nándor / Collaborator ED - Farkas, Orsolya / Collaborator ED - Váncsa, Szilárd / Collaborator ED - Nagy, Rita / Collaborator ED - Bunduc, Stefania / Collaborator ED - Hegyi, Péter Jenő / Collaborator ED - Márta, Katalin / Collaborator ED - Borka, Katalin / Collaborator ED - Doros, Attila / Collaborator ED - Hosszúfalusi, Nóra / Collaborator ED - Zubek, László / Collaborator ED - Erőss, Bálint / Collaborator ED - Molnár, Zsolt / Collaborator ED - Párniczky, Andrea / Collaborator ED - Hegyi, Péter / Collaborator ED - Szentesi, Andrea / Collaborator ED - Bajor, Judit / Collaborator ED - Gódi, Szilárd / Collaborator ED - Sarlós, Patrícia / Collaborator ED - Czimmer, József / Collaborator ED - Szabó, Imre / Collaborator ED - Pár, Gabriella / Collaborator ED - Illés, Anita / Collaborator ED - Hágendorn, Roland / Collaborator ED - Németh, Balázs / Collaborator ED - Kui, Balázs / Collaborator ED - Illés, Dóra / Collaborator ED - Gajdán, László / Collaborator ED - Dunás-Varga, Veronika / Collaborator ED - Fejes, Roland / Collaborator ED - Papp, Mária / Collaborator ED - Vitális, Zsuzsanna / Collaborator ED - Novák, János / Collaborator ED - Török, Imola / Collaborator ED - Macarie, Melania / Collaborator ED - Ramírez-Maldonado, Elena / Collaborator ED - Sallinen, Ville / Collaborator ED - Galeev, Shamil / Collaborator ED - Bod, Barnabás / Collaborator ED - Ince, Ali Tüzün / Collaborator ED - Pécsi, Dániel / Collaborator ED - Varjú, Péter / Collaborator ED - Juhász, Márk Félix / Collaborator ED - Ocskay, Klementina / Collaborator ED - Mikó, Alexandra / Collaborator ED - Szakács, Zsolt / Collaborator AU - Izbéki, Ferenc TI - Early prediction of acute necrotizing pancreatitis by artificial intelligence : a prospective cohort-analysis of 2387 cases JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 12 PY - 2022 IS - 1 PG - 11 SN - 2045-2322 DO - 10.1038/s41598-022-11517-w UR - https://m2.mtmt.hu/api/publication/32823615 ID - 32823615 N1 - * Megosztott szerzőség AB - Pancreatic necrosis is a consistent prognostic factor in acute pancreatitis (AP). However, the clinical scores currently in use are either too complicated or require data that are unavailable on admission or lack sufficient predictive value. We therefore aimed to develop a tool to aid in necrosis prediction. The XGBoost machine learning algorithm processed data from 2387 patients with AP. The confidence of the model was estimated by a bootstrapping method and interpreted via the 10th and the 90th percentiles of the prediction scores. Shapley Additive exPlanations (SHAP) values were calculated to quantify the contribution of each variable provided. Finally, the model was implemented as an online application using the Streamlit Python-based framework. The XGBoost classifier provided an AUC value of 0.757. Glucose, C-reactive protein, alkaline phosphatase, gender and total white blood cell count have the most impact on prediction based on the SHAP values. The relationship between the size of the training dataset and model performance shows that prediction performance can be improved. This study combines necrosis prediction and artificial intelligence. The predictive potential of this model is comparable to the current clinical scoring systems and has several advantages over them. LA - English DB - MTMT ER - TY - JOUR AU - Ocskay, Klementina AU - Vinkó, Zsófia AU - Németh, Dávid AU - Szabó, László AU - Bajor, Judit AU - Gódi, Szilárd AU - Sarlós, Patrícia AU - Czakó, László AU - Izbéki, Ferenc AU - Hamvas, József AU - Papp, Mária AU - Varga, Márta AU - Török, Imola AU - Mickevicius, Artautas AU - Sallinen, Ville AU - Maldonado, Elena Ramirez AU - Galeev, Shamil AU - Mikó, Alexandra AU - Erőss, Bálint Mihály AU - Imrei, Marcell AU - Hegyi, Péter Jenő AU - Faluhelyi, Nándor AU - Farkas, Orsolya AU - Kanizsai, Péter László AU - Miseta, Attila János AU - Nagy, Tamás AU - Hágendorn, Roland AU - Márton, Zsolt AU - Szakács, Zsolt AU - Szentesi, Andrea Ildikó AU - Hegyi, Péter AU - Párniczky, Andrea TI - Hypoalbuminemia affects one third of acute pancreatitis patients and is independently associated with severity and mortality JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 11 PY - 2021 IS - 1 PG - 12 SN - 2045-2322 DO - 10.1038/s41598-021-03449-8 UR - https://m2.mtmt.hu/api/publication/32546426 ID - 32546426 N1 - * Megosztott szerzőség AB - The incidence and medical costs of acute pancreatitis (AP) are on the rise, and severe cases still have a 30% mortality rate. We aimed to evaluate hypoalbuminemia as a risk factor and the prognostic value of human serum albumin in AP. Data from 2461 patients were extracted from the international, prospective, multicentre AP registry operated by the Hungarian Pancreatic Study Group. Data from patients with albumin measurement in the first 48 h (n = 1149) and anytime during hospitalization (n = 1272) were analysed. Multivariate binary logistic regression and Receiver Operator Characteristic curve analysis were used. The prevalence of hypoalbuminemia (< 35 g/L) was 19% on admission and 35.7% during hospitalization. Hypoalbuminemia dose-dependently increased the risk of severity, mortality, local complications and organ failure and is associated with longer hospital stay. The predictive value of hypoalbuminemia on admission was poor for severity and mortality. Severe hypoalbuminemia (< 25 g/L) represented an independent risk factor for severity (OR 48.761; CI 25.276-98.908) and mortality (OR 16.83; CI 8.32-35.13). Albumin loss during AP was strongly associated with severity (p < 0.001) and mortality (p = 0.002). Hypoalbuminemia represents an independent risk factor for severity and mortality in AP, and it shows a dose-dependent relationship with local complications, organ failure and length of stay. LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Anikó AU - Juhász, Márk Félix AU - Görbe, Anikó AU - Váradi, Alex AU - Izbéki, Ferenc AU - Vincze, Áron AU - Sarlós, Patrícia AU - Czimmer, József AU - Szepes, Zoltán AU - Takács, Tamás AU - Papp, Mária AU - Fehér, Eszter AU - Hamvas, József AU - Kárász, Klaudia AU - Török, Imola AU - Stimac, Davor AU - Poropat, Goran AU - Ince, Ali Tüzün AU - Erőss, Bálint Mihály AU - Márta, Katalin AU - Pécsi, Dániel AU - Illés, Dóra AU - Váncsa, Szilárd AU - Földi, Mária AU - Faluhelyi, Nándor AU - Farkas, Orsolya AU - Nagy, Tamás AU - Kanizsai, Péter László AU - Márton, Zsolt AU - Szentesi, Andrea Ildikó AU - Hegyi, Péter AU - Párniczky, Andrea TI - Glucose levels show independent and dose-dependent association with worsening acute pancreatitis outcomes: Post-hoc analysis of a prospective, international cohort of 2250 acute pancreatitis cases JF - PANCREATOLOGY J2 - PANCREATOLOGY VL - 21 PY - 2021 IS - 7 SP - 1237 EP - 1246 PG - 10 SN - 1424-3903 DO - 10.1016/j.pan.2021.06.003 UR - https://m2.mtmt.hu/api/publication/32091062 ID - 32091062 N1 - * Megosztott szerzőség LA - English DB - MTMT ER - TY - JOUR AU - Szakó, Lajos AU - Gede, Noémi AU - Váradi, Alex AU - Tinusz, Benedek AU - Vörhendi, Nóra AU - Mosztbacher, Dóra AU - Vincze, Áron AU - Takács, Tamás AU - Czakó, László AU - Izbéki, Ferenc AU - Gajdán, László AU - Dunás-Varga, Veronika AU - Hamvas, József AU - Papp, Mária AU - Fehér, Krisztina Eszter AU - Varga, Márta AU - Mickevicius, Artautas AU - Török, Imola AU - Ocskay, Klementina AU - Juhász, Márk Félix AU - Váncsa, Szilárd AU - Faluhelyi, Nándor AU - Farkas, Orsolya AU - Miseta, Attila János AU - Vereczkei, András AU - Mikó, Alexandra AU - Hegyi, Péter Jenő AU - Szentesi, Andrea Ildikó AU - Párniczky, Andrea AU - Erőss, Bálint Mihály AU - Hegyi, Péter TI - Early occurrence of pseudocysts in acute pancreatitis - A multicenter international cohort analysis of 2275 cases JF - PANCREATOLOGY J2 - PANCREATOLOGY VL - 21 PY - 2021 IS - 6 SP - 1161 EP - 1172 PG - 12 SN - 1424-3903 DO - 10.1016/j.pan.2021.05.007 UR - https://m2.mtmt.hu/api/publication/32053186 ID - 32053186 N1 - Megosztott utolsó szerzőség AB - Pseudocysts being the most frequent local complications of acute pancreatitis (AP) have substantial effect on the disease course, hospitalization and quality of life of the patient. Our study aimed to understand the effects of pre-existing (OLD-P) and newly developed (NEW-P) pseudocysts on AP.Data were extracted from the Acute Pancreatitis Registry organized by the Hungarian Pancreatic Study Group (HPSG). 2275 of 2461 patients had uploaded information concerning pancreatic morphology assessed by imaging technique. Patients were divided into "no pseudocyst" (NO-P) group, "old pseudocyst" (OLD-P) group, or "newly developed pseudocyst" (NEW-P) groups.The median time of new pseudocyst development was nine days from hospital admission and eleven days from the beginning of the abdominal pain. More NEW-P cases were severe (15.9% vs 4.7% in the NO-P group p < 0.001), with longer length of hospitalization (LoH) (median: 14 days versus 8 days, p < 0.001), and were associated with several changed laboratory parameters. OLD-P was associated with male gender (72.2% vs. 56.1%, p = 0.0014), alcoholic etiology (35.2% vs. 19.8% in the NO-P group), longer hospitalization (median: 10 days, p < 0.001), a previous episode of AP (p < 0.001), pre-existing diagnosis of chronic pancreatitis (CP) (p < 0.001), current smoking (p < 0.001), and increased alcohol consumption (unit/week) (p = 0.014).Most of the new pseudocysts develop within two weeks. Newly developing pseudocysts are associated with a more severe disease course and increased length of hospitalization. Pre-existing pseudocysts are associated with higher alcohol consumption and smoking. Because CP is more frequently associated with a pre-existing pseudocyst, these patients need closer attention after AP. LA - English DB - MTMT ER - TY - JOUR AU - Mikó, Alexandra AU - Erőss, Bálint Mihály AU - Sarlós, Patrícia AU - Hegyi, Péter Jenő AU - Márta, Katalin AU - Pécsi, Dániel AU - Vincze, Áron AU - Bódis, Beáta AU - Nemes, Orsolya AU - Faluhelyi, Nándor AU - Farkas, Orsolya AU - Papp, Róbert AU - Kelemen, Dezső AU - Szentesi, Andrea Ildikó AU - Hegyi, Eszter AU - Papp, Mária AU - Czakó, László AU - Izbéki, Ferenc AU - Gajdán, László AU - Novák, János AU - Sahin-Tóth, Miklós AU - Lerch, Markus M AU - Neoptolemos, John AU - Petersen, Ole H AU - Hegyi, Péter TI - Observational longitudinal multicentre investigation of acute pancreatitis (GOULASH PLUS) : follow-up of the GOULASH study, protocol JF - BMJ OPEN J2 - BMJ OPEN VL - 9 PY - 2019 IS - 8 PG - 9 SN - 2044-6055 DO - 10.1136/bmjopen-2018-025500 UR - https://m2.mtmt.hu/api/publication/30789520 ID - 30789520 AB - Acute pancreatitis (AP) is an inflammatory condition that can lead to late consequences. Recurrent AP (RAP) develops in 20% of patients and chronic pancreatitis (CP) occurs in 7%-12.8%. However, we do not have sufficient information to establish an evidence-based statement to define early CP, or how to prevent its development.The aim of this study was to understand the influencing factors and to determine which parameters should be measured or used as a biomarker to detect the early phase of CP.This is an observational prospective follow-up study of the GOULASH-trial (ISRTCN 63827758) in which (1) all severity of pancreatitis are included; (2) patients receive only therapeutic modalities which are accepted by the evidence based medicine (EBM) guideline; (3) whole blood, serum and plasma samples are stored in our biobank; and (4) large amount of variables are collected and kept in our electronic database including anamnestic data, physical examination, laboratory parameters, imaging, therapy and complications. Therefore, this fully characterised patient cohort are well suitable for this longitudinal follow-up study. Patients' selection: patients enrolled in the GOULASH study will be offered to join to the longitudinal study. The follow-up will be at 1, 2, 3, 4, 5 and 6 years after the episode of AP. Anamnestic data will be collected by questionnaires: (1) diet history questionnaire, (2) 36-Item Short-Form Health Survey, (3) physical activity questionnaire and (4) stress questionnaire. Genetic tests will be performed for the genes associated with CP. The exocrine and endocrine pancreatic, liver and kidney functions will be determined by laboratory tests, stool sample analyses and imaging. Cost-effectiveness will be analysed to examine the relationship between events of interest and health-related quality of life or to explore subgroup differences.This study will provide information about the risk and influencing factors leading to CP and identify the most useful measurable parameters.ISRCTN63396106. LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Arnold AU - Kovács, Noémi AU - Perlaki, Gábor AU - Orsi, Gergely AU - Aradi, Mihály AU - Komáromy, Hedvig AU - Ezer, Erzsébet AU - Bukovics, Péter AU - Farkas, Orsolya AU - Janszky, József Vladimír AU - Dóczi, Tamás Péter AU - Büki, András AU - Schwarcz, Attila TI - Multi-modal magnetic resonance imaging in the acute and sub-acute phase of mild traumatic brain injury: Can we see the difference? JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 30 PY - 2013 IS - 1 SP - 2 EP - 10 PG - 9 SN - 0897-7151 DO - 10.1089/neu.2012.2486 UR - https://m2.mtmt.hu/api/publication/2202895 ID - 2202895 N1 - * Megosztott szerzőség LA - English DB - MTMT ER - TY - JOUR AU - Kövesdi, Erzsébet AU - Lückl, János AU - Bukovics, Péter AU - Farkas, Orsolya AU - Pál, József AU - Czeiter, Endre AU - Szellar, D AU - Dóczi, Tamás Péter AU - Komoly, Sámuel AU - Büki, András TI - Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. JF - ACTA NEUROCHIRURGICA J2 - ACTA NEUROCHIR VL - 152 PY - 2010 IS - 1 SP - 1 EP - 17 PG - 17 SN - 0001-6268 DO - 10.1007/s00701-009-0463-6 UR - https://m2.mtmt.hu/api/publication/1352887 ID - 1352887 N1 - Department of Neurosurgery, University of Pécs, Rét u. 2., 7623 Pécs, Hungary Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States Neurobiology Research Group, Hungarian Academy of Sciences, Pécs, Hungary Department of Neurology, University of Pécs, Pécs, Hungary Cited By :129 Export Date: 1 February 2024 CODEN: ACNUA Correspondence Address: Büki, A.; Department of Neurosurgery, Rét u. 2., 7623 Pécs, Hungary; email: andras.buki@aok.pte.hu AB - This review summarizes protein biomarkers in mild and severe traumatic brain injury in adults and children and presents a strategy for conducting rationally designed clinical studies on biomarkers in head trauma. We performed an electronic search of the National Library of Medicine's MEDLINE and Biomedical Library of University of Pennsylvania database in March 2008 using a search heading of traumatic head injury and protein biomarkers. The search was focused especially on protein degradation products (spectrin breakdown product, c-tau, amyloid-beta(1-42)) in the last 10 years, but recent data on "classical" markers (S-100B, neuron-specific enolase, etc.) were also examined. We identified 85 articles focusing on clinical use of biomarkers; 58 articles were prospective cohort studies with injury and/or outcome assessment. We conclude that only S-100B in severe traumatic brain injury has consistently demonstrated the ability to predict injury and outcome in adults. The number of studies with protein degradation products is insufficient especially in the pediatric care. Cohort studies with well-defined end points and further neuroproteomic search for biomarkers in mild injury should be triggered. After critically reviewing the study designs, we found that large homogenous patient populations, consistent injury, and outcome measures prospectively determined cutoff values, and a combined use of different predictors should be considered in future studies. LA - English DB - MTMT ER - TY - JOUR AU - Czeiter, Endre AU - Bukovics, Péter AU - Farkas, Orsolya AU - Pál, József AU - Kövesdi, Erzsébet AU - Dóczi, Tamás Péter AU - Povlishock, JT AU - Büki, András AU - Sándor, János TI - Calpain inhibition reduces axolemmal leakage in traumatic axonal injury. JF - MOLECULES J2 - MOLECULES VL - 14 PY - 2009 IS - 12 SP - 5115 EP - 5123 PG - 9 SN - 1420-3049 DO - 10.3390/molecules14125115 UR - https://m2.mtmt.hu/api/publication/1352882 ID - 1352882 N1 - Megjegyzés-23799402 : Endre/B-1404-2009 LA - English DB - MTMT ER - TY - THES AU - Farkas, Orsolya TI - A KOPONYATRAUMA ÁLTAL KIVÁLTOTT DIFFÚZ AXONÁLIS ÉS NEURONÁLIS KÁROSODÁS PATHOMECHANIZMUSÁNAK VIZSGÁLATA ÉS TERÁPIÁS BEFOLYÁSOLÁSÁNAK LEHETŐSÉGEI PY - 2008 SP - 137 UR - https://m2.mtmt.hu/api/publication/2239273 ID - 2239273 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kövesdi, Erzsébet AU - Tamás, Andrea AU - Reglődi, Dóra AU - Farkas, Orsolya AU - Pál, József AU - Tóth, Gábor AU - Bukovics, Péter AU - Dóczi, Tamás Péter AU - Büki, András TI - Posttraumatic administration of pituitary adenylate cyclase activating polypeptide in central fluid percussion injury in rats JF - NEUROTOXICITY RESEARCH J2 - NEUROTOX RES VL - 13 PY - 2008 IS - 2 SP - 71 EP - 78 PG - 8 SN - 1029-8428 DO - 10.1007/BF03033558 UR - https://m2.mtmt.hu/api/publication/1166819 ID - 1166819 AB - Several in vitro and in vivo experiments have demonstrated the neuroprotective effects of pituitary adenylate cyclase activating polypeptide (PACAP) in focal cerebral ischemia, Parkinson's disease and traumatic brain injury (TBI). The aim of the present study was to analyze the effect of PACAP administration on diffuse axonal injury (DAI), an important contributor to morbidity and mortality associated with TBI, in a central fluid percussion (CFP) model of TBI. Rats were subjected to moderate (2 Atm) CFP injury. Thirty min after injury, 100 microg PACAP was administered intracerebroventricularly. DAI was assessed by immunohistochemical detection of beta-amyloid precursor protein, indicating impaired axoplasmic transport, and RMO-14 antibody, representing foci of cytoskeletal alterations (neurofilament compaction), both considered classical markers of axonal damage. Analysis of damaged, immunoreactive axonal profiles revealed significant axonal protection in the PACAP-treated versus vehicle-treated animals in the corticospinal tract, as far as traumatically induced disturbance of axoplasmic transport and cytoskeletal alteration were considered. Similarly to our former observations in an impact acceleration model of diffuse TBI, the present study demonstrated that PACAP also inhibits DAI in the CFP injury model. The finding indicates that PACAP and derivates can be considered potential candidates for further experimental studies, or purportedly for clinical trials in the therapy of TBI. LA - English DB - MTMT ER -